Download ii cancer cell signaling pathways conference

II CANCER CELL SIGNALING PATHWAYS
CONFERENCE
AN IN DEPTH LOOK AT LUNG, MELANOMA, GLIOBLASTOMA, BREAST, HEAD &
NECK SQUAMOUS CELL CANCERS
Institut Germans Trias i Pujol (IGTP), Conference Meeting Room,
Badalona, Barcelona, Spain - July 6th, 2017
Organized by: Rafael Rosell, Imane Chaib, Maria Gonzalez-Cao and Niki Karachaliou
Graphical Abstract
Highlights:
Co-activation of receptor tyrosine kinases and non-receptor tyrosine kinases is a common
feature in cancer. Cross-talk between different signaling pathways is the basis for polytherapy in several tumors. Rewiring of cell signals occurs as a response to therapy.
PROGRAM
08:30: Welcome
8:45 – 9:00: Cell maps for gauging the evolution of cancer
- Rafael Rosell, Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology,
Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain
SESSION I
Chairpersons: Miguel Angel Molina and Niki Karachaliou
9:00 – 9:30: Signal transducer and activator of transcription 3 (STAT3) and YES-associated protein
1 (YAP1) signaling in EGFR mutant non-small-cell lung cancer limits targeted therapy response
Targeted pathway inhibitors (western blots and in vitro viability assays)
- Imane Chaib, Cancer Biology & Precision Medicine Program , Germans Trias i Pujol Health
Sciences Institute, Badalona, Spain
Mouse models and quantitative RT- PCR in EGFR mutant NSCLC patients
- Niki Karachaliou, IOR, Hospital Sagrat Cor and Coyote Research Group, Pangaea Oncology,
Quiron-Dexeus Hospital, Barcelona, Spain
9:30 - 9:45: Discussion
9:45 – 10:15: The missing view in cancer biology and the contribution of patients’ families
- Lars Soraas, Oslo, Norway
- Jo Monsen, Oslo, Norway
10:15 – 10:30: The view of the clinical investigator
- Nuno Gil, Champalimaud Cancer Center, Lisbon, Portugal
10:30 – 10:45: Coffee Break
SESSION II
Chairpersons: Niki Karachaliou and Miguel Angel Molina
10:45 – 12:15: Co-activation of receptor tyrosine and non-receptor tyrosine kinases in EGFR
mutant NSCLC
Phospho-receptor kinase antibody arrays and immunofluorescence
- Jordi Berenguer, Coyote Research Group, Pangaea Oncology, Quiron-Dexeus
Hospital, Barcelona, Spain
Quantitative RT-PCR and colony formation assays
- Jill Bracht, Coyote Research Group, Pangaea Oncology, Quiron-Dexeus Hospital,
Barcelona, Spain
In vitro viability assays to audit TPX-0005, cabozantinib, dasatinib and HP90i
- Imane Chaib, Cancer Biology & Precision Medicine Program , Germans Trias i Pujol
-
Health Sciences Institute, Badalona, Spain
Jordi Codony, Coyote Research Group, Pangaea Oncology, Quiron-Dexeus Hospital,
Barcelona, Spain
Jill Bracht, Coyote Research Group, Pangaea Oncology, Quiron-Dexeus Hospital,
Barcelona, Spain
Concomitant or alternate treatment with EGFR TKIs
- Jordi Berenguer, Coyote Research Group, Pangaea Oncology, Quiron-Dexeus
Hospital, Barcelona, Spain
Differential sensitivity with gefitinib, osimertinib, afatinib and dacomitinib
- Marta Horcas, Cancer Biology & Precision Medicine Program , Germans Trias i Pujol
Health Sciences Institute, Badalona, Spain
Mouse models
- Niki Karachaliou, IOR, Hospital Sagrat Cor and Coyote Research Group, Pangaea Oncology,
Quiron-Dexeus Hospital, Barcelona, Spain
Phase I clinical trial with osimertinib (or other EGFR TKIs) plus TPX-0005 in first line EGFR
mutant NSCLC
- Niki Karachaliou, IOR, Hospital Sagrat Cor and Coyote Research Group, Pangaea Oncology,
Quiron-Dexeus Hospital, Barcelona, Spain
12:15 – 12:30: Discussion
SESSION III
Chairpersons: Imane Chaib, Jose Luis Ramirez
12:30 – 12:45: Squamous cell carcinoma of the lung
- Alberto Verlicchi, SC Oncologia. Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
12:45 – 13:15: Squamous cell carcinoma of head and neck
- Rafael Rosell, Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology,
Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain
13:15 – 13:30: RESPONSE project: Exploiting chromatin for drug response
- Marcus Buschbeck, Josep Carreras Leukaemia Research Institute, Germans Trias i Pujol Health
Sciences Institute, Badalona, Spain
13:30 – 13:45: Relevance of PTPRT mutations and STAT3 signaling
- Jose Luis Ramirez, Cancer Biology & Precision Medicine Program, Catalan Institute of
Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain
13:45 – 14:00: Discussion and Lunch
SESSION IV
Chairpersons: Carles Codony, Maria de los Llanos Gil
14:00 – 14:15: KRAS mutant NSCLC
Tracking signaling pathways
- Chiara Lazzari, Dept. of Oncology, Division of Experimental Medicine, IRCCS San
Raffaele, Milan, Italy
In vitro viability assays to audit different targeted combinations
- Carles Codony, Coyote Research Group, Pangaea Oncology, Quirón-Dexeus Hospital,
Barcelona, Spain
14:15 – 14:30: Discussion
SESSION V
Chairpersons: Luis Montuenga, Santiago Ramon y Cajal
14:30 – 14:45: New insights in MNKs
- Santiago Ramón y Cajal, Pathology Dept. Vall d’ Hebron University Hospital, Barcelona, Spain
14:45 – 15:00: The relevance of paracrine cross-talk in lung carcinogenesis
- Luis M. Montuenga, Center for Applied Medical Research, CIMA, Pamplona, Spain
15:00 – 15:15: Discussion
15:15 – 15:30: Interferon gamma signaling pathway and response to immune checkpoint inhibitors
in NSCLC and melanoma
- Maria Gonzalez Cao, IOR, Quiron-Dexeus Hospital, Barcelona, Spain
15:30 – 15:45: Intratumor heterogeneity in small-cell-lung cancer and NOTCH signaling
- Niki Karachaliou, IOR, Hospital Sagrat Cor and Coyote Research Group, Pangaea Oncology,
Quiron-Dexeus Hospital, Barcelona, Spain
SESSION VI
Chairpersons: Andres Felipe Cardona, Miguel Angel Molina
15:45 – 16:00: AXL in triple negative breast cancer
- Libero Santarpia, Coyote Research Group, Pangaea Oncology, Quiron-Dexeus Hospital,
Barcelona, Spain
16:00 – 16:15: Discussion
16:15 – 16:30: EGFR mutations in early resected NSCLC
- Masaoki Ito, Coyote Research Group, Pangaea Oncology, Quiron-Dexeus Hospital, Barcelona,
Spain
-
16:30 – 16:45: EGFR mutations in Latin America
-
Andres Felipe Cardona, Clinica del Country, Bogota, Colombia
16:45 – 17:00: Discussion/Coffee break
SESSION VII
Chairpersons: Bartomeu Massuti, Santiago Viteri
17:00 – 17:15: SLCG clinical trials
- Bartomeu Massuti, Hospital General de Alicante, Spain
17:15 – 17:30: Improving clinical trials
- Alejandro Martinez Bueno, IOR, Quiron-Dexeus Hospital, Barcelona, Spain
17:30 – 17:45: Moving forward with clinical trials
- François Riva, MedSir, Barcelona, Spain
17:45 – 18:00: Immune checkpoint inhibitor therapy in HIV positive cancer patients
- Maria Gonzalez Cao, IOR, Quiron-Dexeus Hospital, Barcelona, Spain
18:00 – 18:30: Round Table:
Views on amalgamating research for improving cancer care
- Chairs: Bartomeu Massuti and Santiago Viteri
- Nuno Gil, Lars Soraas, Jo Monsen, François Riva, Alejandro Martinez Bueno, Niki
Karachaliou, Maria Gonzalez Cao, Andres Felipe Cardona, Masaoki Ito
18:30: CLOSING REMARKS
Cancer Biology and Precision Medicine Laboratory
Supporting companies
For free registration, click on the link below :
For more general information, here is the meeting web::
How to get to the IGTP/IMPPC
By car / taxi:
We are 20 minutes from the center of the city and the most convenient way to arrive is by car or
taxi. We are close to the Hospital which can serve as a good point of reference:
Hospital Universitari Germans Trias I Pujol (Popularly known as Can Rutí)
GPS: 41°29’06.66”N 2°14’21.27”E
From Barcelona take B20 (Rondas and Nus de la Trinitat) in direction Mataró. The hospital is well
signed from the exit 21 (Badalona Centre) of the B20.
With the collaboration of Harvey Evans, Lourdes Franquet and Stephanie Davis